FDA Panel Rejects Pimavanserin for Alzheimer’s Psychosis
A US Food and Drug Administration (FDA) advisory panel has rejected the atypical antipsychotic pimavanserin (Nuplazid, Acadia Pharmaceuticals) for the treatment of Alzheimer’s disease psychosis (ADP). In a 9-3 vote, the Psychopharmacologic Drugs Advisory Committee (PDAC) found that the drug’s manufacturer failed to offer convincing evidence of its efficacy in patients with ADP. Today’s rejection … Read more